Related Experiment Video
Updated: Dec 11, 2025
Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
Published on: January 19, 2024
How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?
Arihant Jain1, Charanpreet Singh1, Rishi Dhawan2
1Department of Internal Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012 India.
Insights
This review addresses the challenges and solutions for managing patients with hematological disorders during the COVID-19 pandemic. It offers disease-specific recommendations to guide clinical decision-making and policy formulation.
Area of Science:
- Hematology
- Infectious Diseases
- Public Health
Background:
- The COVID-19 pandemic poses significant risks to patients with hematological disorders and comorbidities.
- Healthcare systems face potential overwhelm due to community transmission of SARS-CoV-2.
- Limited evidence exists for managing hematologic conditions during the pandemic.
Purpose of the Study:
- To summarize challenges faced by clinicians managing hematologic patients during the COVID-19 pandemic.
- To provide key considerations and decision-making guidance.
- To suggest solutions and disease-specific recommendations feasible within healthcare settings.
Main Methods:
- Literature review on COVID-19 impact on hematological disorders.
- Synthesis of current evidence and clinical experience.
- Development of disease-specific management recommendations.
Main Results:
- Identified key challenges in patient care and resource allocation.
- Outlined critical considerations for clinical decision-making.
- Proposed practical, adaptable recommendations for various hematologic diseases.
Conclusions:
- Clinicians require tailored guidance for managing hematologic patients during pandemics.
- The review provides a template for local policy development.
- Individual clinical judgment remains paramount in patient care.
Abstract:
The current pandemic coronavirus, SARS-CoV-2, is known to cause severe infection (COVID-19) in patients with comorbidities, particularly cancer or an immunosuppressed state. Most healthcare systems in the country are likely to be overwhelmed soon if the pandemic moves to a stage of community transmission. Currently, limited evidence is available for managing patients with hematological disorders during the COVID-19 pandemic. The current review summarises the possible challenges clinicians are likely to face, key considerations to guide decision making, and possible solutions to the anticipated challenges. Disease specific recommendations and possible guidance for decision making have been suggested for most hematologic diseases that are feasible in our health setup. It is not meant to replace individual clinical judgment, but to provide a template to formulate local policies.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
01:26Standard Precaution
Hand hygiene is the most crucial means to prevent the transmission of disease. Employers are legally required to provide their workers with personal protective equipment (PPE) to minimize exposure or contact with...
01:21Hematopoiesis
01:17Transmission-based Precautions I: Contact, Enteric, and Droplets
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: